A new Flagship startup looks to crack tRNA biology in search for completely new class of therapeutics
With Moderna and its mRNA-based vaccine acting as a proof of concept, Flagship Pioneering has dived headfirst into tapping other forms of RNA as potential game changers in drug development. Now, another Flagship brand is off and running with a first-of-its-kind programmable platform looking to unlock the secrets of transfer RNA.
Alltrna launched Tuesday with $50 million in funding from Flagship and years of work behind the scenes building expertise from scratch in adapting learnings from inside the cell into a growing therapeutic platform based around tRNA biology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.